Other OTC - Delayed Quote USD

Lifeline Biotechnologies, Inc. (LLBO)

0.0002 0.0000 (0.00%)
As of May 2 at 3:56 PM EDT. Market Open.
Loading Chart for LLBO
DELL
  • Previous Close 0.0002
  • Open 0.0002
  • Bid --
  • Ask --
  • Day's Range 0.0002 - 0.0002
  • 52 Week Range 0.0001 - 0.0040
  • Volume 1,040,000
  • Avg. Volume 114,425
  • Market Cap (intraday) 10.986M
  • Beta (5Y Monthly) -1.52
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast; and OVASCOPE, an ultra slim endoscope to directly visualize the ovarian surface in the search for cancer. The company also has operations in Europe. Lifeline Biotechnologies, Inc. was incorporated in 1981 and is headquartered in Reno, Nevada.

www.lbti.co

--

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: LLBO

Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LLBO
0.00%
S&P 500
7.55%

1-Year Return

LLBO
0.00%
S&P 500
24.52%

3-Year Return

LLBO
91.30%
S&P 500
22.69%

5-Year Return

LLBO
88.24%
S&P 500
75.83%

Compare To: LLBO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LLBO

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -574.27k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    603.32k

  • Total Debt/Equity (mrq)

    7.89%

  • Levered Free Cash Flow (ttm)

    --

Company Insights: LLBO

People Also Watch